DelveInsight’s “Attention Deficit Hyperactivity Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Attention Deficit Hyperactivity Disorder, historical and forecasted epidemiology as well as the Attention Deficit Hyperactivity Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Attention Deficit Hyperactivity Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Attention Deficit Hyperactivity Disorder Market Forecast
Some of the key facts of the Attention Deficit Hyperactivity Disorder Market Report:
-
The Attention Deficit Hyperactivity Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
In March 2023, Cingulate and Indegene have entered into a collaborative commercialization agreement aimed at offering commercial assistance for Cingulate’s primary candidate CTx-1301 (dexmethylphenidate) intended for attention-deficit/hyperactivity disorder (ADHD), once endorsed by the US Food and Drug Administration (FDA). This partnership encompasses comprehensive services across various functions, employing an omnichannel marketing strategy tailored specifically to oversee pre-commercial support during Cingulate’s Phase 3 clinical trials and to efficiently introduce CTx-1301 nationwide upon potential FDA approval.
-
In February 2023, Pharmanovia has broadened its neurology offerings with a fresh licensing deal with Axsome Therapeutics, Inc., headquartered in the US. Under this agreement, Pharmanovia secures exclusive marketing privileges for Sunosi (solriamfetol) and gains the opportunity to investigate solriamfetol’s potential in additional neurological disorders, including attention deficit hyperactivity disorder (ADHD).
-
In February 2023, Cingulate reported encouraging initial findings from the CTx-1301-003 study, evaluating the impact of food on the absorption of its primary candidate CTx-1301. CTx-1301, an innovative, investigational extended-release tablet formulation of dexmethylphenidate, an FDA-approved compound for attention deficit/hyperactivity disorder (ADHD) treatment, was the subject of the trial. Results indicated that CTx-1301 can be administered with or without food. The study included multiple pharmacokinetic (PK) assessments, and observed adverse events were consistent with prior observations, suggesting a favorable tolerability profile.
-
In January 2023, NLS Pharmaceutics Ltd. disclosed that the Patents Registry of the Intellectual Property Department in The Government of the Hong Kong Special Administrative Region has approved Patent Application 42022055879.5. This patent pertains to the utilization of Mazindol ER for the treatment of ADHD and is projected to remain valid until at least 2037.
-
In January 2023, ABVC BioPharma, Inc. revealed that Dr. Keith McBurnett, a Psychiatry Professor at the University of California San Francisco, presented findings from the Phase IIa investigation of its medical intervention, ABV-1505 ADHD, on January 14, 2023, at the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session. The Phase IIa study utilized the active pharmaceutical ingredient PDC-1421, contained in ABV-1505, involving six adult subjects with confirmed ADHD. Results indicated that both low and high doses of PDC-1421 were safe, well-tolerated, and effective throughout the treatment and subsequent follow-up period.
-
According to the ADHD Institute, a global average prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents (under 18 years old) is estimated at 2.2%, with a range from 0.1% to 8.1%.
-
In a research study led by Riedel et al. (2021), the age- and sex-standardized prevalence of Attention Deficit Hyperactivity Disorder (ADHD) varied between 37.2 per 1,000 individuals in 2009 and 43.5 per 1,000 individuals in 2015, encompassing all the data years examined.
-
Key Attention Deficit Hyperactivity Disorder Companies: Otsuka Pharmaceuticals, ABVC BioPharma, Inc, Cingulate Therapeutics, GlaxoSmithKline, New River Pharmaceuticals, DSM Nutritional Products, Inc., Mind Medicine, Inc., Materia Medica Holding, Arbor Pharmaceuticals, Inc., Pfizer, Tris Pharma, Inc., Janssen Korea, Ltd., Korea, Janssen Pharmaceutical K.K., and others
-
Key Attention Deficit Hyperactivity Disorder Therapies: Centanafadine, ABV-1505, CTx-1301, Extended-release bupropion hydrochloride, Vyvanse (lisdexamfetamine dimesylate), NRP104, DHA Omega-3, MM-120, Prospecta, Amphetamine Sulfate, Quillivant Oral Suspension XR, TRI102, OROS Methylphenidate HCL, JNS001, and others
-
The Attention Deficit Hyperactivity Disorder epidemiology based on gender analyzed that ADHD diagnosis by a physician or psychologist is significantly more prevalent for boys (7.9%) than for girls (1.8%).
-
The Attention Deficit Hyperactivity Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Attention Deficit Hyperactivity Disorder pipeline products will significantly revolutionize the Attention Deficit Hyperactivity Disorder market dynamics.
Attention Deficit Hyperactivity Disorder Overview
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that commonly affects children but can persist into adulthood. It is characterized by a persistent pattern of inattention, hyperactivity, and impulsivity that interferes with daily functioning and development.
Get a Free sample for the Attention Deficit Hyperactivity Disorder Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Attention Deficit Hyperactivity Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Attention Deficit Hyperactivity Disorder Epidemiology Segmentation:
The Attention Deficit Hyperactivity Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Attention Deficit Hyperactivity Disorder
-
Prevalent Cases of Attention Deficit Hyperactivity Disorder by severity
-
Gender-specific Prevalence of Attention Deficit Hyperactivity Disorder
-
Diagnosed Cases of Episodic and Chronic Attention Deficit Hyperactivity Disorder
Download the report to understand which factors are driving Attention Deficit Hyperactivity Disorder epidemiology trends @ Attention Deficit Hyperactivity Disorder Epidemiology Forecast
Attention Deficit Hyperactivity Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Attention Deficit Hyperactivity Disorder market or expected to get launched during the study period. The analysis covers Attention Deficit Hyperactivity Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Attention Deficit Hyperactivity Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Attention Deficit Hyperactivity Disorder Therapies and Key Companies
-
Centanafadine: Otsuka Pharmaceuticals
-
ABV-1505: ABVC BioPharma, Inc
-
CTx-1301: Cingulate Therapeutics
-
Extended-release bupropion hydrochloride: GlaxoSmithKline
-
Vyvanse (lisdexamfetamine dimesylate), NRP104: New River Pharmaceuticals
-
DHA Omega-3: DSM Nutritional Products, Inc.
-
MM-120: Mind Medicine, Inc.
-
Prospecta: Materia Medica Holding
-
Amphetamine Sulfate: Arbor Pharmaceuticals, Inc.
-
Quillivant Oral Suspension XR: Pfizer
-
TRI102: Tris Pharma, Inc.
-
OROS Methylphenidate HCl: Janssen Korea, Ltd., Korea
-
JNS001: Janssen Pharmaceutical K.K.
Discover more about therapies set to grab major Attention Deficit Hyperactivity Disorder market share @ Attention Deficit Hyperactivity Disorder Treatment Landscape
Scope of the Attention Deficit Hyperactivity Disorder Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Attention Deficit Hyperactivity Disorder Companies: Otsuka Pharmaceuticals, ABVC BioPharma, Inc, Cingulate Therapeutics, GlaxoSmithKline, New River Pharmaceuticals, DSM Nutritional Products, Inc., Mind Medicine, Inc., Materia Medica Holding, Arbor Pharmaceuticals, Inc., Pfizer, Tris Pharma, Inc., Janssen Korea, Ltd., Korea, Janssen Pharmaceutical K.K., and others
-
Key Attention Deficit Hyperactivity Disorder Therapies: Centanafadine, ABV-1505, CTx-1301, Extended-release bupropion hydrochloride, Vyvanse (lisdexamfetamine dimesylate), NRP104, DHA Omega-3, MM-120, Prospecta, Amphetamine Sulfate, Quillivant Oral Suspension XR, TRI102, OROS Methylphenidate HCL, JNS001, and others
-
Attention Deficit Hyperactivity Disorder Therapeutic Assessment: Attention Deficit Hyperactivity Disorder current marketed and Attention Deficit Hyperactivity Disorder emerging therapies
-
Attention Deficit Hyperactivity Disorder Market Dynamics: Attention Deficit Hyperactivity Disorder market drivers and Attention Deficit Hyperactivity Disorder market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Attention Deficit Hyperactivity Disorder Unmet Needs, KOL’s views, Analyst’s views, Attention Deficit Hyperactivity Disorder Market Access and Reimbursement
To know more about Attention Deficit Hyperactivity Disorder companies working in the treatment market, visit @ Attention Deficit Hyperactivity Disorder Clinical Trials and Therapeutic Assessment
Table of Contents
1. Attention Deficit Hyperactivity Disorder Market Report Introduction
2. Executive Summary for Attention Deficit Hyperactivity Disorder
3. SWOT analysis of Attention Deficit Hyperactivity Disorder
4. Attention Deficit Hyperactivity Disorder Patient Share (%) Overview at a Glance
5. Attention Deficit Hyperactivity Disorder Market Overview at a Glance
6. Attention Deficit Hyperactivity Disorder Disease Background and Overview
7. Attention Deficit Hyperactivity Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Attention Deficit Hyperactivity Disorder
9. Attention Deficit Hyperactivity Disorder Current Treatment and Medical Practices
10. Attention Deficit Hyperactivity Disorder Unmet Needs
11. Attention Deficit Hyperactivity Disorder Emerging Therapies
12. Attention Deficit Hyperactivity Disorder Market Outlook
13. Country-Wise Attention Deficit Hyperactivity Disorder Market Analysis (2019–2032)
14. Attention Deficit Hyperactivity Disorder Market Access and Reimbursement of Therapies
15. Attention Deficit Hyperactivity Disorder Market Drivers
16. Attention Deficit Hyperactivity Disorder Market Barriers
17. Attention Deficit Hyperactivity Disorder Appendix
18. Attention Deficit Hyperactivity Disorder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/